FAP and neoplasm: Preclinical studies in cells expressing human and murine FAP and CD26 resulted in an increased half-life of 3.0 h for [177Lu]Lu-FAPi-04, versus 1.7 h for [177Lu]Lu-FAPi-02 in the tumor.